David Walt - Illumina Director

ILMN Stock  USD 137.32  1.36  0.98%   

Director

Dr. David R. Walt Ph.D. is no longer Chairman Scientific Advisory Board Independent Director of Illumina Inc. since June 1998. Dr. Walt was the Robinson Professor of Chemistry at Tufts University since 1995 and was a Howard Hughes Medical Institute Professor since 2006. Dr. Walt is a Member of the National Academy of Engineering a Fellow of the American Institute of Medical and Biological Engineers and a Fellow of the American Association for the Advancement of Science. Dr. Walt has published over 250 papers and is named as an inventor or coinventor of over 60 patents many of which are directed to microarray products. He also serves as a board member for Quanterix Inc. a privatelyheld company focused on single molecule analysis for clinical diagnostics and AuraSense LLC a privatelyheld company focused on developing therapeutic agents based on spherical nucleic acids since 1998.
Age 62
Tenure 26 years
Professional MarksPh.D
Address 5200 Illumina Way, San Diego, CA, United States, 92122
Phone858 202 4500
Webhttps://www.illumina.com
Walt holds a B.S. in Chemistry from the University of Michigan and received his Ph.D. in Chemical Biology from SUNY at Stony Brook.

David Walt Latest Insider Activity

Tracking and analyzing the buying and selling activities of David Walt against Illumina stock is an integral part of due diligence when investing in Illumina. David Walt insider activity provides valuable insight into whether Illumina is net buyers or sellers over its current business cycle. Note, Illumina insiders must abide by specific rules, including filing SEC forms every time they buy or sell Illumina'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

Illumina Management Efficiency

As of the 29th of March 2024, Return On Capital Employed is likely to drop to -0.0086. In addition to that, Return On Assets is likely to grow to -0.11. At this time, Illumina's Total Assets are very stable compared to the past year. As of the 29th of March 2024, Non Current Assets Total is likely to grow to about 7.9 B, while Non Currrent Assets Other are likely to drop about 123.4 M. Illumina's management efficiency ratios could be used to measure how well Illumina manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 2.26 B in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Illumina has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Illumina until it has trouble settling it off, either with new capital or with free cash flow. So, Illumina's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Illumina sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Illumina to invest in growth at high rates of return. When we think about Illumina's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Allen KamerDarioHealth Corp
45
Matthew NortonMedpace Holdings
30
Peter NeupertLaboratory
65
Kerrii AndersonLaboratory
63
Heinrich DreismannMyriad Genetics
63
Bahija JallalGuardant Health
56
Robert MittelstaedtLaboratory
74
Dipchand NisharGuardant Health
N/A
JeanLuc BelingardLaboratory
72
Alexander LeslieMedpace Holdings
35
Dennis McGrathDarioHealth Corp
60
Robert WilliamsLaboratory
72
Guy InnesVolitionrx
60
John RichardsonMedpace Holdings
33
Sanders WilliamsLaboratory
69
Supraj RajagopalanMedpace Holdings
38
Aaref HilalyGuardant Health
46
Fred DavenportMedpace Holdings
66
Dennis LangerMyriad Genetics
65
Robert KraftMedpace Holdings
47
Glen MollerDarioHealth Corp
N/A
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. The company was incorporated in 1998 and is based in San Diego, California. Illumina operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 9800 people. Illumina (ILMN) is traded on NASDAQ Exchange in USA. It is located in 5200 Illumina Way, San Diego, CA, United States, 92122 and employs 10,590 people. Illumina is listed under Life Sciences Tools & Services category by Fama And French industry classification.

Management Performance

Illumina Leadership Team

Elected by the shareholders, the Illumina's board of directors comprises two types of representatives: Illumina inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Illumina. The board's role is to monitor Illumina's management team and ensure that shareholders' interests are well served. Illumina's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Illumina's outside directors are responsible for providing unbiased perspectives on the board's policies.
Paula Dowdy, Senior Vice President and General Manager
Richard Klausner, Chief Medical Officer & Interim General Manager, Oncology
Karen McGinnis, Vice President Chief Accounting Officer, Principal Accounting Officer
David Walt, Founder, Director and Member of Nominating and Corporate Governance Committee
Philip Schiller, Director
Roy Whitfield, Independent Director
Jeffrey Huber, Director
Pat Leckman, Interim Officer
Aimee Hoyt, Senior Vice President and Chief People Officer
Garret Hampton, Executive Vice President - Clinical Genomics
John Thompson, Director
Frances Arnold, Director
Christian Henry, Chief Commercial Officer and Executive VP
Caroline Dorsa, Director
Daniel Bradbury, Independent Director
Nicholas Naclerio, Senior Vice President Corporate Development & General Manager - Enterprise Informatics
Susan Siegel, Director
Susan Tousi, Chief Officer
Omead Ostadan, Executive Vice President - Operations, Products and Strategy
Phillip Febbo, Chief Medical Officer
Steven Barnard, Chief Officer
Stephanie Campos, President
William Rastetter, Independent Chairman of the Board
Jacquie Ross, Vice President Investor Relations
Robert Epstein, Independent Director
Paul Bianchi, Senior Vice President - Human Resources
Jonathan Seaton, Senior Vice President - Corporate & Business Development
Francis deSouza, Pres and Director
Jacob Thaysen, CEO Director
Karin Eastham, Independent Director
Charles Dadswell, Senior Vice President General Counsel, Secretary
Rebecca Chambers, Senior Director - Investor Relations
Sanjay Chikarmane, Senior Vice President General Manager
Sam Samad, CFO, Senior Vice President
Scott Ericksen, VP Officer
Kevin Pegels, Chief Operations
Charles Esq, Senior Counsel
Joydeep MBA, Chief CFO
Sallilyn Schwartz, Vice Relations
Mark Oene, Senior Vice President Chief Commercial Officer
Arthur Bowman, Independent Director
Gary Guthart, Director
Kathryne Reeves, Chief Officer
Jay Flatley, Chairman and CEO
Mostafa Ronaghi, CTO, Senior Vice President
Alexander MD, CTO Devel
Carissa Rollins, Chief Officer
Tristan Orpin, Senior Vice President & General Manager, Reproductive and Genetic Health
Marc Stapley, CFO, Chief Admin. Officer and Executive VP

Illumina Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Illumina a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Illumina Investors Sentiment

The influence of Illumina's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Illumina. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Illumina's public news can be used to forecast risks associated with an investment in Illumina. The trend in average sentiment can be used to explain how an investor holding Illumina can time the market purely based on public headlines and social activities around Illumina. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Illumina's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Illumina's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Illumina's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Illumina.

Illumina Implied Volatility

    
  40.83  
Illumina's implied volatility exposes the market's sentiment of Illumina stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Illumina's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Illumina stock will not fluctuate a lot when Illumina's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Illumina in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Illumina's short interest history, or implied volatility extrapolated from Illumina options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Illumina offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Illumina's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Illumina Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Illumina Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Illumina. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
To learn how to invest in Illumina Stock, please use our How to Invest in Illumina guide.
You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.

Complementary Tools for Illumina Stock analysis

When running Illumina's price analysis, check to measure Illumina's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Illumina is operating at the current time. Most of Illumina's value examination focuses on studying past and present price action to predict the probability of Illumina's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Illumina's price. Additionally, you may evaluate how the addition of Illumina to your portfolios can decrease your overall portfolio volatility.
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Is Illumina's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Illumina. If investors know Illumina will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Illumina listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.96)
Earnings Share
(7.35)
Revenue Per Share
28.506
Quarterly Revenue Growth
0.036
Return On Assets
(0.01)
The market value of Illumina is measured differently than its book value, which is the value of Illumina that is recorded on the company's balance sheet. Investors also form their own opinion of Illumina's value that differs from its market value or its book value, called intrinsic value, which is Illumina's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Illumina's market value can be influenced by many factors that don't directly affect Illumina's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Illumina's value and its price as these two are different measures arrived at by different means. Investors typically determine if Illumina is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Illumina's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.